Evidence map›Paper›PMID 28160600›Full record

ArticleNucleic acids research2017

The lncRNA VELUCT strongly regulates viability of lung cancer cells despite its extremely low abundance.

Jana Seiler, Marco Breinig, Maïwen Caudron-Herger, Maria Polycarpou-Schwarz, Michael Boutros, Sven Diederichs

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. LAFITE Reveals the Complexity of Transcript Isoforms in Subcellular Fractions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  10. Article
  11. Article
  12. Designing libraries for pooled CRISPR functional screens of long noncoding RNAs.Mammalian genome : official journal of the International Mammalian Genome Society · 2022
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jana SeilerDivision of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marco BreinigDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maïwen Caudron-HergerDivision of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maria Polycarpou-SchwarzDivision of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael BoutrosDivision of Signaling and Functional Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sven DiederichsDivision of RNA Biology & Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Little is known about the function of most non-coding RNAs (ncRNAs). The majority of long ncRNAs (lncRNAs) is expressed at very low levels and it is a matter of intense debate whether these can be of functional relevance. Here, we identified lncRNAs regulating the viability of lung cancer cells in a high-throughput RNA interference screen. Based on our previous expression profiling, we designed an siRNA library targeting 638 lncRNAs upregulated in human cancer. In a functional siRNA screen analyzing the viability of lung cancer cells, the most prominent hit was a novel lncRNA which we called Viability Enhancing LUng Cancer Transcript (VELUCT). In silico analyses confirmed the non-coding properties of the transcript. Surprisingly, VELUCT was below the detection limit in total RNA from NCI-H460 cells by RT-qPCR as well as RNA-Seq, but was robustly detected in the chromatin-associated RNA fraction. It is an extremely low abundant lncRNA with an RNA copy number of less than one copy per cell. Blocking transcription with actinomycin D revealed that VELUCT RNA was highly unstable which may partially explain its low steady-state concentration. Despite its extremely low abundance, loss-of-function of VELUCT with three independent experimental approaches in three different lung cancer cell lines led to a significant reduction of cell viability: Next to four individual siRNAs, also two complex siPOOLs as well as two antisense oligonucleotides confirmed the strong and specific phenotype. In summary, the extremely low abundant lncRNA VELUCT is essential for regulation of cell viability in several lung cancer cell lines. Hence, VELUCT is the first example for a lncRNA that is expressed at a very low level, but has a strong loss-of-function phenotype. Thus, our study proves that at least individual low-abundant lncRNAs can play an important functional role.

Indexed as

Cell Line, TumorCell ProliferationCell SurvivalChromatinGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingHumansLung NeoplasmsRNA, Long NoncodingRNA, MessengerRNA, Small InterferingRNA StabilityChromatinRNA, Long NoncodingRNA, MessengerRNA, Small Interfering

Identifiers

PMID28160600
PMCPMC5435915
OpenAlexW2584328606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.